Chapter 83 Yun Cong! (Ask for monthly ticket)
There are not a few people like Zhou Zeping who come back from thousands of miles away.
When Tsingshan Pharmaceutical announced that the Phase III clinical trial of "Icofenprovir" would achieve a 90% cure rate, hepatitis B patients from all over the country and from all walks of life followed suit one after another!
It has to be said that because of the existence of the "Starlight Project", all hepatitis B projects follow the green approval channel, and "Acofenprofovir" also enjoys rapid approval.
The clinical phase II review was passed in just 20 working days, and the clinical phase III trial protocol was approved simultaneously!
On November 10, "Acofenprofovir" will officially start Phase III clinical trials.
But in fact,
Before the official opening on November 10th, a large number of patients from all over the country poured into Chengdu Third People's Hospital on November 1st to start registration applications. Participated in the third clinical phase of "Ecofovir".
On November 3, in just three days, all 600 test places for "Ecofovir", which was originally slow to recruit in the second phase, were taken up!
At this time, no matter what cytotoxicity or side effects, they all seem unimportant when facing the 90% probability of curing hepatitis B!
Deputy Director Feng Gang was shocked. He had never seen any new drug recruit 600 subjects in just three days, and there was a steady stream of subjects coming!
But think about it, in China, there is no virus that can spread as widely, have such a large impact, and be as harmful as hepatitis B!
Not for diabetes, not for high blood pressure, not even for the epidemic virus!
Feng Gang was amazed that Director Chen Wen of the Department of Infectious Diseases was in pain and happiness.
Since participating in clinical trials requires a series of examinations and the establishment of medical records, the influx of a large number of patients has made the entire infectious disease department extremely busy.
In fact,
Compared to other departments, the Infectious Disease Department is regarded as a "clean water clinic", and the overall revenue and profit of the department is not much. In addition, the Infectious Disease Department of the third-party medical department is not a star department. On weekdays, the doctors in the department , the performance pay of nurses is minimal.
Don’t they want to make more money?
Think about it!
But there are no infected patients in the hospital, what can we do?
Now, a large number of hepatitis B patients are pouring in. Not only the outpatient doctors are full every day, but even the inpatient departments are nearly full!
The entire department, from the director to the nurses, are all suffering and happy. I truly feel the busyness and happiness of the hematology department back then!
Of course.
The happiest person is Dean Zhou.
When he mobilized department doctors to help advance the second clinical phase of "Ecofovir", he actually wanted to return a favor.
Unexpectedly, Qingshan Pharmaceutical is really up to date!
He watched helplessly as the cure rate of "Ecofovir" increased step by step from the initial 25% to 60%, and now it is reaching 90%!
Indirectly, it even led to the rapid development of the Department of Infectious Diseases and Hepatology of the entire Third People's Hospital!
With such energy, his heart couldn't help but become active!
You must know that every department across the country has annual selections every year. Currently, the Third People's Hospital of Chengdu only has the only "Hematology Department" ranked in the top 20...
This time there is an influx of so many hepatitis B patients because of "Acofovir". At the same time, there will inevitably be a large number of hepatitis B patients admitted to the hospital for treatment. If we can seize this opportunity, the ranking of the infectious disease department may not be able to advance further. !
His eyes became brighter and brighter. Last year, he was personally praised by the leaders of the General Administration for the hematology department's leading position in the clinical use of "Avatrombopag Tablets" and the cure of aplastic anemia.
If I mention the ranking of the Department of Infectious Diseases again.
“Zhang Yang, you are truly my noble person!”
……
Just when Dean Zhou wanted to make more progress, news of the Phase II clinical data of Tsingshan Pharmaceutical's "Ikefenprovir" and the imminent start of the Phase III clinical trial also spread abroad.
United States, Gilead Pharmaceutical Company.
"Daniel, we must admit that we have underestimated the R&D capabilities of this Chinese pharmaceutical company."
"I have carefully looked at their R&D progress. Starting from 25% effective cure, 45% %, 60%, they are moving very steadily and smoothly step by step.”
“And, most importantly, their research and development ideas are really novel, and the results are really unexpectedly good. ”
“Far exceeded my expectations!”
The speaker was John, Vice President of Research and Development at Gilead Headquarters. He and President Daniel have been old partners for more than ten years.
Daniel nodded, approval flashing in his eyes.
In fact, since they learned that "Ecofovir" has a 25% healing effect, they began to study "Ecofovir", which was also known as "QS-001" at the time.
I didn’t expect that Qingshan Pharmaceutical’s next research and development speed would be too fast.
The reason is undoubtedly that Qingshan Pharmaceutical has found the best way to solve the hepatitis B virus!
“Yes, John, I completely agree with you.”
“The most important reason why they were able to achieve significant results so quickly is that they found the right and most correct way. !”
“To tell you the truth, their research and development ideas and their toxic substances have provided me with a lot of inspiration.”
“So, they are completely worthy of their reputation. ! ”
The two of them affirmed "Acofuvir" without hesitation. Because both of them knew that when Gilead was developing a drug to cure hepatitis C, it had no clue at first. After discovering the best solution, the cure rate increased from 20% to 95% in just six months.
It is exactly the same as the current "Ecofovir".
"Then what should we do next?"
Vice President John shrugged and said:
"Currently, their 'Ecofovir' has a high probability of achieving a 90% cure rate, and they will also win the scientific research funds for the 'Starlight Project' this time."
"Next What should we do with our Hepcludex project? Stop it completely or give up?”
Daniel didn’t answer directly, frowning slightly in thought.
In fact, when major pharmaceutical companies around the world conduct research and development of multiple drugs, they will only invest a small amount of the company's resources and funds at the beginning. This is casting a wide net.
When one of the projects really achieves some breakthrough progress, the company will pool resources and invest more R&D funds in order to focus the funds on the most promising drugs.
Benefiting from the "Starlight Project", Gilead has invested hundreds of millions of dollars in its hepatitis B drug Hepcludex. If it stops at this time, it means that almost all the initial investment will be in vain.
This is the cruelty of research and development in the pharmaceutical industry.
A few minutes later, Daniel shook his head slightly:
“It would be a pity to give up completely, after all, we have invested so much money, and Hepcludex has also made good progress.”
< br>"Let the R&D team continue to develop. Of course, we can no longer invest a lot of resources without scruples as before. After all, 'Ekofuvir' is already one step ahead of us."
Vice President John nodded, he completely agreed with Daniel's statement.
The pharmaceutical industry is not like other industries. It has a process of accumulation. Maybe this drug does not succeed, but the accumulated experience and ideas will lead to success in another new drug.
"Then should we continue to develop hepatitis B drugs, or should we learn from Tsingshan Pharmaceutical's research and development ideas for 'Ecofovir'?"
"Why not?"
This time Daniel didn’t hesitate at all:
"Their idea of solving hepatitis B virus is very novel. It is something we have never thought of or tried before."
"Although they are one step ahead of us now, even if they can really achieve a 90% cure rate, they will not be able to achieve a cure rate of 90%." Drug toxicity and side effects can continue to be improved.”
“There are more than 300 million hepatitis B patients in the world, as long as we can make improvements. Similar drugs may not have sales, and! ”
“AIDS and hepatitis B belong to the same double-stranded structure of CCDNA. If we can use Qingshan Pharmaceutical’s idea to cure hepatitis B, we may not be able to use this idea to cure AIDS in the future.”< br>
“So, what reason do we have for not learning from the best ideas in the world?”
John smiled.
The character of this old partner has never changed no matter how much money he makes.
Daniel has been learning, and Gilead has been learning too.
This is also the reason why Gilead is so strong in the fields of liver diseases and infectious diseases.
“Okay, Daniel, I will arrange for the R&D team to start seriously studying Qingshan Pharmaceutical’s ‘Ecofovir’.”
"I think it won't be long before we can fully understand the drug mechanism."
...
PS: I saw everyone's latest comments, and they all said they were a bit watery.
It’s not a little bit, it’s very watery.
I humbly accept it. The reason is not that I am deliberately misleading, but that my perception may be slightly different from that of the readers! We also welcome your comments and corrections, and we will work hard to make corrections in the future.
I sincerely ask for a few monthly passes. It would be too pitiful to not have a monthly pass today.
(End of this chapter)